Quality of life and Eating disorders in women with Polycystic Ovary Syndrome
Abstract
INTRODUCTION: Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting women worldwide, posing a major public health concern. This multifaceted condition significantly impairs quality of life (QOL) across multiple domains.
AIM: To assess QOL and eating disorders (EDs) in patients with PCOS.
METHODS: A cross-sectional descriptive and comparative study was conducted on women with confirmed PCOS who were followed in the Endocrinology Department of Hedi Chaker Hospital, Sfax, Tunisia, and a targeted group of women with PCOS recruited through Google Forms. The PCOSQ-42 questionnaire for unmarried women, the PCOSQ-47 for married women, and the SCOFF questionnaire were used as assessment tools. Participants were divided into two groups: Group 1, consisting of French participants, and Group 2, consisting of Tunisian participants.
RESULTS: A total of 71 French participants (Group 1) and 101 Tunisian participants (Group 2) were included in the study. All participants reported a compromised QOL. Among married women, the psychological well-being domain had the lowest score (2.86 ± 0.7), while the menstrual and fertility disorders domain was the most affected among unmarried women, with an average score of 2.84 ± 0.8. EDs were identified in 70.93% of participants, with a higher prevalence among unmarried women. A better QOL was observed among married women in Group 2 compared to their counterparts in Group 1.
CONCLUSION: The findings reveal a high prevalence of impaired…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 101 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.